Bortezomib overcomes TRAIL resistance in Burkitt's lymphoma by enhancing apoptosis via reactive oxygen species-mediated DR5 upregulation and MAPK pathway activation.

ABSTRACT: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells and exerts minimal toxic effects on normal cells. However, resistance to TRAIL-induced apoptosis is a major obstacle in the clinical application of TRAIL. Bortezomib can enhance the tumor-killing effect of TRAIL in certain tumors, but understanding in Burkitt's lymphoma (BL), especially in TRAIL-resistant BL cells, is limited. Therefore, the present study aimed to assess the synergistic effect of bortezomib and TRAIL in BL. Using the Raji cell line, the least susceptible to TRAIL among BL cell lines, the present study assessed the effect and mechanism by which bortezomib reverses resistance to TRAIL. Cell proliferation inhibition was assessed using the Cell Counting Kit-8 assay. Apoptosis was asse

SUBMITTER: Chen J 

PROVIDER: S-EPMC12557187 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature